Autonomous multi-agent research engine that synthesizes pharmacovigilance signals, drug discovery data, and clinical trial landscapes from authoritative public databases. Every cited identifier is grounded against the source records actually retrieved during the run, any citation not grounded in retrieved evidence is flagged, and cited DOIs are screened against Crossref for retractions. At delivery, each cited PMID, NCT, and DOI is additionally re-resolved against its issuing registry (NCBI E-utilities, ClinicalTrials.gov, Crossref) and recorded — VERIFIED, UNRESOLVED, or UNCHECKED — in a Reproducibility Manifest shipped with the report. Resolution confirms an identifier resolves to a source record; it does not assess the source’s scientific conclusions.
Request a Report → Request Sample Deliverable View ProductsAdverse event signal detection, AEMS (formerly FAERS, daily updates since Aug 2025) disproportionality analysis, drug interaction profiling, and clinical action recommendations across compound cohorts.
Compound profiling with ADMET properties, target-compound mapping, molecular interaction networks, and competitive landscape analysis.
Global trial mapping, endpoint analysis, enrollment trends, competitor pipeline tracking, and regulatory milestone timelines.
Multi-omics target-disease association scoring, genetic evidence mapping, tissue expression profiling, and druggability assessment.
Autonomous scan of FDA registries, peer-reviewed literature, and pharmacological databases. Cross-reference normalization across identifier systems (PMID, NCT, RxNorm, PubChem CID, UniProt).
Disproportionality metrics (ROR, PRR), drug interaction matrices, pharmacokinetic and pharmacodynamic profiling with molecular-level specificity.
Signal hierarchy integrating scout and analyst outputs. Contradiction resolution, confidence tier assignment, and actionable clinical or strategic recommendations.
Automated enforcement of citation density and grounding thresholds: every cited identifier is checked against the source records retrieved at runtime (ungrounded cites flagged), cited DOIs are retraction-screened against Crossref, and an append-only evidence ledger with SHA-256 chain-hashed integrity tracks provenance.
Each AWS Marketplace subscription provisions a dedicated Amazon S3 bucket. Citation-traced research dossiers, citation-index CSVs, and provenance manifests land directly in the subscriber's bucket on a defined schedule.
Citation indexes ship as Parquet alongside the markdown report. Subscribers query the index directly with Amazon Athena — filter by PMID, NCT, ChEMBL CID, or DOI; join against internal pipeline data; build dashboards on top.
Output schemas are compatible with Amazon Redshift Data Sharing and Snowflake Secure Data Sharing. Federate dossier metadata into your existing analytics warehouse; enrich with your own RWE, claims, or trial data — no ETL pipeline to maintain.
trevor-robey-inc data products are available through AWS Data Exchange for biotech investors, hedge funds, and pharma BD/licensing teams running portfolio diligence on AWS. Discoverable in the AWS Marketplace catalog; subscribed to with one click; billed through your existing AWS account.
| Type | Identifier | Context |
|---|---|---|
| PMID | 30232222 | ICI myocarditis systematic review, JACC 2018 |
| NCT | NCT00302159 | Valproic acid + temozolomide in GBM |
| RxNorm | 1597876 | Nivolumab (Opdivo) pharmacology |
| DOI | 10.1056/NEJMoa1716078 | NEJM: ICI cardiac adverse events |
| UniProt | P11712 | CYP2C9 enzyme — VPA/TMZ interaction |
Every identifier above is a real public-domain identifier you can look up in its source database. Check PMID:30232222 at pubmed.ncbi.nlm.nih.gov — it resolves to Wang et al., JACC 2018.
Request Full Sample